|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's range||92.56 - 95.29|
|52-week range||75.22 - 198.00|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||57.48|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||23 Nov 2012|
|1y target est||N/A|
Masimo's (MASI) receipt of the latest FDA approval is expected to provide greater visibility of changes in oxygen saturation to help patients better manage their oxygen levels daily.
Masimo's (MASI) latest joint effort is likely to enable real-time continuous monitoring with a tailored view of the patient's vitals while keeping them mobile during critical recovery periods.
Masimo Corporation (NASDAQ:MASI) Q3 2023 Earnings Call Transcript November 7, 2023 Masimo Corporation misses on earnings expectations. Reported EPS is $0.1967 EPS, expectations were $0.59. Operator: Good afternoon, ladies and gentlemen, and welcome to Masimo’s Third Quarter 2023 Earnings Conference Call. The company’s press release is available at www.masimo.com. [Operator Instructions] I am pleased to […]